Follistatin 344 FST
Myostatin and activin binder
Secreted glycoprotein, here the 344-amino-acid isoform, that binds and neutralises myostatin and activins; studied for muscle mass in animals.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Myostatin and activin binder
- Category
- Muscle & Growth Factors
- Type
- Single compound
- Abbreviation
- FST
- Development and regulatory status
- Investigational (gene-therapy trials); protein not approved
What researchers study
Secreted glycoprotein, here the 344-amino-acid isoform (circulating as FS315), that binds and neutralises myostatin and activins and raised muscle mass in animal studies. Its activin binding can also suppress pituitary FSH secretion.
Research areas
- Myostatin pathway and muscle-mass models
- Activin and FSH axis interactions
- Gene-transfer muscle disease studies
- Isoform comparisons (FS344 versus FS288)
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- human trial
AAV1 gene transfer of follistatin FS344 in six inclusion-body myositis patients was followed by +56.0 m/year in six-minute walk versus -25.8 m/year in untreated matched controls
- review
A review describes the first clinical gene-transfer trial using FS344, in Becker muscular dystrophy, and preclinical evidence of increased muscle mass after follistatin gene delivery
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
